ArticleHeart rhythm O22026
Does obesity affect atrial fibrillation ablation outcomes? Insights from a national atrial fibrillation catheter ablation registry: One-year follow-up.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pulsed Field Ablation for Atrial Fibrillation in Obesity: Reassessing Risk, Safety, and Success.Journal of clinical medicine · 2026Review
- Single-shot AF ablation, Leadless pacemakers and LAAO are EP, not IC procedures.Indian pacing and electrophysiology journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is the most common sustained arrhythmia in adults and is associated with significant morbidity and mortality. Obesity is a known risk factor for AF, but its impact on the success of AF ablation and the risk of recurrence remains inconclusive. Objective: This study evaluated the safety and efficacy of AF ablation across different obesity subgroups. Methods: This prospective, nationwide, multicenter registry study included 878 patients who underwent AF ablation between January 2019 and December 2021. Participants were categorized into nonobese and obesity classes I-III (body mass index [BMI] ≥30 kg/m Results: AF recurrence at 1 year occurred in 23% of patients, with no significant differences among BMI groups. In multivariable analysis, none of the obesity subgroups were independently associated with recurrent AF or need for reablation. Female gender, systolic pulmonary artery pressure, and left atrium size were significant predictors of AF recurrence. Rehospitalization rates were higher in obesity classes I (adjusted hazard ratio 2.2; Conclusion: This study suggests that although obesity is associated with a higher rate of rehospitalization, it does not significantly affect the 12-month efficacy or safety of AF ablation. These findings support the continued use of AF ablation in obese patients, regardless of obesity class.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.